Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sometimes the older formulation of tenofovir is a better choice for HIV prevention.
Little HIV prevention research has included pregnant women for fear of adverse birth outcomes.
The U.S. government clarified that health insurers must cover PrEP and the associated doctor visits and tests. Here’s why.
Awareness of the HIV prevention pills don’t match their use.
HIV clinics could lose over $100 million each year—notably those serving Black, brown, queer and Southern communities.
Several formulations of generic Truvada are now available at a lower cost.
The HIV prevention bill now heads to the Oregon Senate. Here’s why better PrEP and PEP access could help Latinos and Black Americans.
Study also finds that trans girls are more likely to receive gender-affirming care than trans boys.
An East Harlem HIV prevention campaign focuses on Black and Latino New Yorkers at higher risk.
Enrollees in the national Ready, Set, PrEP program can now have their meds delivered via mail at no cost.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
Studies of the link between tenofovir use and coronavirus infection or COVID-19 outcomes have yielded mixed results.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.